癌症研究
医学
体内
转移
癌症
受体
AMPA受体
癌细胞
谷氨酸受体
旁分泌信号
腹膜腔
药理学
靶向治疗
腹膜
病理
信号转导
激酶
作者
Jie Sun,Xu Yang,Wenchao Jiang,Chengbo Ji,Yingying Wu,Han Sun,Xinyou Liu,Masami Yamamoto,Tetsuya Tsukamoto,Sachiyo Nomura,Junjie Zhao,Yuanyuan Ruan,Haojie Li,Xuefei Julie Wang
标识
DOI:10.1002/advs.202521746
摘要
Peritoneal metastasis is the most lethal manifestation of gastric cancer, with a median survival of less than one year, highlighting the need for new therapeutic targets. Through an in vivo genome-wide CRISPR/Cas9 screen, we identified GRIA2, an AMPA-type glutamate receptor subunit, as a key driver of peritoneal metastasis. GRIA2 promotes gastric cancer cell migration, invasion, stemness, and adhesion to mesothelial cells in a glutamate-dependent manner. Mechanistically, glutamate activates GRIA2, enhancing its interaction with GSK-3β and inducing calcium influx, inhibiting GSK-3β kinase activity and stabilizing β-catenin, thereby activating the Wnt/β-catenin signaling pathway. Single-cell RNA sequencing revealed that cancer-associated fibroblasts are the primary source of glutamate in the peritoneal microenvironment, which establishes a paracrine axis that enhances GRIA2-driven metastasis. Pharmacological inhibition of AMPA receptors with NBQX and Selurampanel suppressed peritoneal metastasis in both cell line-derived and patient-derived organoid xenograft (PDOX) mouse models. In clinical analysis, GRIA2 expression in peritoneal metastases correlated with the levels of β-catenin and phosphorylated GSK-3β (serine 9), with high GRIA2 expression predicting poor prognosis. These findings suggest that GRIA2 is a novel therapeutic target, and AMPA receptor antagonists are promising agents for treating gastric cancer peritoneal metastasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI